Staphylococcus aureus Bacteremia (SAB) Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies | DelveInsight

Staphylococcus aureus Bacteremia (SAB) is projected to boom by 2036 as new therapies and diagnostics expand the market for treating bloodstream infections. DelveInsight, a market research firm, released a report titled “DelveInsight's Staphylococcus aureus Bacteremia (SAB) Market Insights, Epidemiology, and Market Forecast - 2036,” citing rising incidence of bloodstream infections, higher prevalence of methicillin-resistant Staphylococcus aureus (MRSA), and greater adoption of rapid diagnostic technologies. The study estimates that SAB treatment market value in the 7MM (United States, EU4—Germany, Spain, Italy, France—, the UK, and Japan) will grow from about USD 1.5 billion in 2022 to nearly USD 4.3 billion by 2036. The report links the burden to nosocomial infections, referencing SENTRY surveillance where S. aureus accounted for 26.0% of hospital-acquired bacteremia cases in the US and 19.5% in Europe. DelveInsight also highlights emerging treatments such as AP-SA02 and XF-73. Companies named include Armata Pharmaceuticals, Destiny Pharma/EMV Capital, and Basilea Pharmaceutica.